Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL359 Target Snapshot

Bacillus subtilis · ORGANISM · Bacillus subtilis

Back to Search Search this target Browse approvals Evidence Card
23,488Compounds
3,838Assays
13Approved Drugs
649.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Bacillus subtilis as ChEMBL target CHEMBL359. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Bacillus subtilis
ORGANISM · Bacillus subtilis
As of 2026-09-13
ChEMBL target ID
CHEMBL359
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Bacillus subtilis still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameBacillus subtilis
Target TypeORGANISM
OrganismBacillus subtilis
ChEMBL ↗ NCBI Taxonomy ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelBacillus subtilis
UniProt AccessionN/A

Bacillus subtilis

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Bacillus subtilis.

Review nameBacillus subtilis
OrganismBacillus subtilis
Clinical Profile

Clinical Phase Distribution

13
Approved
2
Phase III
1
Phase II
Assay Mix

Activity Type Distribution

IC50602.0
EC5037.0
KD10.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4175069 8.43 IC50 3.7 Preclinical
CHEMBL4164425 8.24 IC50 5.8 Preclinical
CHEMBL4176131 8.03 IC50 9.3 Preclinical
CHEMBL4164850 7.98 IC50 10.4 Preclinical
CHEMBL4163914 7.92 IC50 12.0 Preclinical
CHEMBL4172757 7.91 IC50 12.4 Preclinical
CHEMBL4168288 7.35 IC50 45.0 Preclinical
CHEMBL1632145 7.0 EC50 100.0 Preclinical
CHEMBL2296999 6.89 IC50 130.0 Preclinical
CHEMBL1384 6.87 IC50 135.0 Approved
Distribution

pChEMBL Value Distribution

50
5.0
33
5.5
16
6.0
18
6.5
2
7.0
3
7.5
3
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

CIPROFLOXACIN
CHEMBL8
Approved 1987
Properties Compare Identifier
MITOMYCIN
CHEMBL105
Approved 1981
Properties Compare Identifier
AMOXICILLIN
CHEMBL1082
Approved 1974
Properties Compare Identifier
KANAMYCIN
CHEMBL1384
Approved 1973
Properties Compare Identifier
TRIMETHOPRIM
CHEMBL22
Approved 1973
Properties Compare Identifier
CEPHALEXIN ANHYDROUS
CHEMBL1727
Approved 1971
Properties Compare Identifier
AMPICILLIN
CHEMBL174
Approved 1965
Properties Compare Identifier
ERYTHROMYCIN
CHEMBL532
Approved 1964
Properties Compare Identifier
Assay Landscape

Assay Landscape

3,853
Total Assays
295
Tested Compounds
3
Assay Types
Functional — 3,843 assays, 295 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 3,638 290 5.4
assay format 205 5 5.7
ADME — 5 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 5 0 —
Toxicity — 5 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 5 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine